Home › Funds › Propel Bio Management, LLC › FDMT
Propel Bio Management, LLC position in FDMT
4D MOLECULAR THERAPEUTICS IN · Health Care
Propel Bio Management, LLC reported holding 179,154 shares of FDMT (4D MOLECULAR THERAPEUTICS IN) in its Q3 2026 13F filing — a position valued at US$2.6M, representing 1.36% of its reported portfolio and ranking #23 among its reported holdings. Propel Bio Management, LLC has disclosed FDMT holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Propel Bio Management, LLC's FDMT position evolved
Propel Bio Management, LLC first disclosed a stake in FDMT in Q1 2026 at 380,420 shares (US$3.6M). Across 3 filings, Propel Bio Management, LLC increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 179,154 shares valued at US$2.6M — a reduction of -73,500 shares quarter over quarter.. Notable position changes include a 34% trim in Q2 2026 (shares rose 8% over the following quarter), a 29% trim in Q3 2026 (shares fell 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 380.42K | $3.58M | New |
| Q2 2026 | 252.65K | $3.36M | Reduce |
| Q3 2026 | 179.15K | $2.56M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About FDMT and 13F data
FDMT (4D MOLECULAR THERAPEUTICS IN) is a Health Care company. 38 other funds we track also report a position in FDMT — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.2M), Novo Holdings A/S (US$43.2M), BVF INC/IL (US$38.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FDMT
- RA CAPITAL MANAGEMENT, L.P. 5.05M sh · $67.16M · Q2 2026
- Novo Holdings A/S 3.25M sh · $43.21M · Q2 2026
- BVF INC/IL 2.88M sh · $38.29M · Q2 2026
- Trails Edge Capital Partners, LP 2.23M sh · $29.63M · Q2 2026
- ARMISTICE CAPITAL, LLC 2.00M sh · $26.60M · Q2 2026
- Evergreen Quality Fund GP, Ltd. 951.47K sh · $12.65M · Q2 2026
- Parkman Healthcare Partners LLC 948.18K sh · $12.61M · Q2 2026
- DIADEMA PARTNERS LP 571.11K sh · $7.60M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 507.80K sh · $6.75M · Q2 2026
- Catalio Capital Management, LP 471.25K sh · $6.27M · Q2 2026
- Opaleye Management Inc. 334.44K sh · $4.45M · Q2 2026
More on Propel Bio Management, LLC
FAQ
How long has Propel Bio Management, LLC held FDMT?
Propel Bio Management, LLC has disclosed FDMT holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Propel Bio Management, LLC's current position in FDMT?
As of Q3 2026, Propel Bio Management, LLC holds 179.15K shares of FDMT (4D MOLECULAR THERAPEUTICS IN), valued at $2.56M, representing 1.36% of its reported portfolio and ranking #23.
Has Propel Bio Management, LLC been buying or selling FDMT?
In the latest 13F filing (Q3 2026), Propel Bio Management, LLC reduced its position in FDMT.
Which other funds hold FDMT?
Other major institutional holders of FDMT include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, BVF INC/IL, among 38 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.